JP2019534034A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534034A5 JP2019534034A5 JP2019531512A JP2019531512A JP2019534034A5 JP 2019534034 A5 JP2019534034 A5 JP 2019534034A5 JP 2019531512 A JP2019531512 A JP 2019531512A JP 2019531512 A JP2019531512 A JP 2019531512A JP 2019534034 A5 JP2019534034 A5 JP 2019534034A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- antigen
- binding fragment
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610705763.5A CN106977602B (zh) | 2016-08-23 | 2016-08-23 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN201610705763.5 | 2016-08-23 | ||
| PCT/CN2017/098465 WO2018036472A1 (zh) | 2016-08-23 | 2017-08-22 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534034A JP2019534034A (ja) | 2019-11-28 |
| JP2019534034A5 true JP2019534034A5 (enExample) | 2020-07-16 |
| JP7082620B2 JP7082620B2 (ja) | 2022-06-08 |
Family
ID=59340342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531512A Active JP7082620B2 (ja) | 2016-08-23 | 2017-08-22 | 抗ｐｄ１モノクローナル抗体、その医薬組成物およびその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12076398B2 (enExample) |
| EP (2) | EP4509186A3 (enExample) |
| JP (1) | JP7082620B2 (enExample) |
| KR (1) | KR102469286B1 (enExample) |
| CN (1) | CN106977602B (enExample) |
| AU (2) | AU2017316255C1 (enExample) |
| BR (1) | BR112019003775A2 (enExample) |
| EA (1) | EA201990570A1 (enExample) |
| ES (1) | ES3001154T3 (enExample) |
| FI (1) | FI3505535T3 (enExample) |
| HU (1) | HUE069593T2 (enExample) |
| IL (1) | IL264956B2 (enExample) |
| LT (1) | LT3505535T (enExample) |
| MX (1) | MX2019002268A (enExample) |
| NZ (1) | NZ751902A (enExample) |
| PL (1) | PL3505535T3 (enExample) |
| PT (1) | PT3505535T (enExample) |
| RS (1) | RS66372B1 (enExample) |
| SG (1) | SG11201901584UA (enExample) |
| SI (1) | SI3505535T1 (enExample) |
| WO (1) | WO2018036472A1 (enExample) |
| ZA (1) | ZA201901781B (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| KR20250099459A (ko) | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| CN106977602B (zh) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| IL272159B2 (en) | 2017-08-04 | 2026-03-01 | Genmab As | PD-L1 and CD137 binding agents and their use |
| CN109425736B (zh) * | 2017-08-25 | 2021-04-09 | 北京百普赛斯生物科技股份有限公司 | 一种检测pd-1抗体血药浓度的方法及试剂盒 |
| KR20200059243A (ko) * | 2017-09-20 | 2020-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| EP3773916A4 (en) * | 2018-04-04 | 2021-12-15 | TrueBinding, Inc. | PROCEDURES AND COMPOSITIONS FOR BLOCKING THE INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES |
| WO2019217457A1 (en) | 2018-05-07 | 2019-11-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| CA3099547A1 (en) | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| WO2020015703A1 (zh) | 2018-07-18 | 2020-01-23 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与抗体的药物组合 |
| CN109053889B (zh) * | 2018-07-25 | 2019-06-21 | 博奥信生物技术（南京）有限公司 | 一种抗人pd1单克隆抗体及用途 |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| PL3946377T3 (pl) | 2019-04-03 | 2026-04-20 | Orega Biotech | Terapie skojarzone oparte na inhibitorach pd1 i il-17b |
| CN110373415B (zh) * | 2019-06-12 | 2023-06-09 | 安徽省昂普拓迈生物科技有限责任公司 | 特异性结合pd-l1蛋白的核酸适配体及其用途 |
| KR20220030956A (ko) | 2019-07-05 | 2022-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | Pd-1/cd3 이중 특이성 단백질에 의한 혈액암 치료 |
| CN112300286A (zh) * | 2019-08-02 | 2021-02-02 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
| KR20220062503A (ko) | 2019-08-02 | 2022-05-17 | 씨티티큐-아케소 (상하이) 바이오메드. 테크. 컴퍼니, 리미티드 | 항-pd-1 항체 및 이의 약제학적 용도 |
| TW202120550A (zh) | 2019-08-08 | 2021-06-01 | 日商小野藥品工業股份有限公司 | 雙特異性蛋白質 |
| CN110903391B (zh) * | 2019-10-25 | 2021-05-28 | 东大生物技术(苏州)有限公司 | 一组pd-l1单克隆抗体及其医药用途 |
| CN112915202B (zh) * | 2019-12-06 | 2025-08-01 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| EP4079763A4 (en) * | 2019-12-20 | 2023-10-11 | Guangdong Feipeng Pharmaceutical Co., Ltd | MONOCLONAL ANTIBODY AGAINST HUMAN PROGRAMMED DEATH-1 (PD-1) |
| CN113117072A (zh) * | 2020-01-14 | 2021-07-16 | 正大天晴药业集团股份有限公司 | 喹啉衍生物与pd-1单抗的药物组合 |
| US20230045494A1 (en) | 2020-02-28 | 2023-02-09 | Orega Biotech | Combination therapies based on ctla4 and il-17b inhibitors |
| KR20230004726A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73/항-pd-1 이중특이항체 및 이의 용도 |
| KR20230003178A (ko) | 2020-04-29 | 2023-01-05 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | PD-1 및 TGF-β에 대한 이중 기능성 단백질 |
| CN113754767A (zh) * | 2020-06-03 | 2021-12-07 | 上海恒润达生生物科技股份有限公司 | 抗人pd-1抗体及其用途 |
| CN114761434B (zh) * | 2020-09-30 | 2023-06-27 | 苏州沙砾生物科技有限公司 | Pd-1抗体及其制备方法与应用 |
| US20240024320A1 (en) | 2020-11-17 | 2024-01-25 | Seagen Inc. | Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody |
| CN113336848B (zh) * | 2021-02-03 | 2022-08-19 | 上海莱馥医疗科技有限公司 | 一种抗pd-1抗体及其用途 |
| US20250114450A1 (en) * | 2021-03-12 | 2025-04-10 | Akeso Biopharma, Inc. | Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| CN115873116B (zh) | 2021-09-29 | 2026-04-28 | 中山康方生物医药有限公司 | 抗lag3抗体、药物组合物及用途 |
| IL311771A (en) | 2021-10-06 | 2024-05-01 | BioNTech SE | Multispecific binding agents against pd-l1 and cd137 in combination |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| CN113912710B (zh) * | 2021-11-17 | 2023-05-26 | 杭州旭科生物技术有限公司 | 抗新型冠状病毒n蛋白的单克隆抗体及其应用 |
| CN117069850B (zh) * | 2021-12-20 | 2025-02-14 | 南京诺唯赞检测技术有限公司 | 一种vce的单克隆抗体及其制备方法 |
| EP4257609A1 (en) | 2022-04-08 | 2023-10-11 | iOmx Therapeutics AG | Combination therapies based on pd-1 inhibitors and sik3 inhibitors |
| CN119031933B (zh) * | 2022-04-12 | 2025-08-26 | 正大天晴(广州)医药有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
| CA3253038A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | LIAISON AGENTS CAPABLE OF BINDING TO CD27 IN POLYTHERAPY |
| US11932693B2 (en) | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
| US20250282873A1 (en) * | 2022-05-13 | 2025-09-11 | Nanjing Shunxin Pharmaceuticals Co., Ltd. Of Chiatai Tianqing Pharmaceutical Group | Drug combination of anti-tim-3 antibody and anti-pd-1 antibody |
| CN119789867A (zh) * | 2022-09-06 | 2025-04-08 | 正大天晴药业集团股份有限公司 | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |
| US20260098092A1 (en) * | 2022-10-05 | 2026-04-09 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
| CN117986356B (zh) * | 2022-10-27 | 2025-07-22 | 纽迈生物科技(苏州)有限公司 | 一种制备抗体的方法 |
| CN120302979A (zh) | 2022-12-01 | 2025-07-11 | 生物技术公司 | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 |
| EP4688160A1 (en) | 2023-04-06 | 2026-02-11 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| US12410258B2 (en) | 2023-05-12 | 2025-09-09 | Ganmab A/S | Antibodies capable of binding to OX40, variants thereof and uses thereof |
| WO2025056014A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| CN118652343B (zh) * | 2024-07-08 | 2025-05-09 | 吉林省医菲尼迪生物医药有限公司 | 一种临床血液免疫细胞以及在治疗疾病中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) * | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| PL2342226T3 (pl) * | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP2545073B1 (en) | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| MX341076B (es) * | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104250302B (zh) * | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| DK3049441T3 (da) | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| HUE046249T2 (hu) * | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN104974253A (zh) | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| CN104987421A (zh) | 2015-05-13 | 2015-10-21 | 北京比洋生物技术有限公司 | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 |
| CN105175544B (zh) | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
| CN105175545B (zh) * | 2015-10-20 | 2019-01-25 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| CN105754990A (zh) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
-
2016
- 2016-08-23 CN CN201610705763.5A patent/CN106977602B/zh active Active
-
2017
- 2017-08-22 SI SI201731577T patent/SI3505535T1/sl unknown
- 2017-08-22 PT PT178428959T patent/PT3505535T/pt unknown
- 2017-08-22 WO PCT/CN2017/098465 patent/WO2018036472A1/zh not_active Ceased
- 2017-08-22 JP JP2019531512A patent/JP7082620B2/ja active Active
- 2017-08-22 RS RS20250001A patent/RS66372B1/sr unknown
- 2017-08-22 US US16/327,083 patent/US12076398B2/en active Active
- 2017-08-22 NZ NZ751902A patent/NZ751902A/en unknown
- 2017-08-22 LT LTEPPCT/CN2017/098465T patent/LT3505535T/lt unknown
- 2017-08-22 EP EP24206755.1A patent/EP4509186A3/en active Pending
- 2017-08-22 ES ES17842895T patent/ES3001154T3/es active Active
- 2017-08-22 SG SG11201901584UA patent/SG11201901584UA/en unknown
- 2017-08-22 BR BR112019003775-6A patent/BR112019003775A2/pt active Search and Examination
- 2017-08-22 EP EP17842895.9A patent/EP3505535B1/en active Active
- 2017-08-22 PL PL17842895.9T patent/PL3505535T3/pl unknown
- 2017-08-22 KR KR1020197008464A patent/KR102469286B1/ko active Active
- 2017-08-22 MX MX2019002268A patent/MX2019002268A/es unknown
- 2017-08-22 HU HUE17842895A patent/HUE069593T2/hu unknown
- 2017-08-22 FI FIEP17842895.9T patent/FI3505535T3/fi active
- 2017-08-22 EA EA201990570A patent/EA201990570A1/ru unknown
- 2017-08-22 AU AU2017316255A patent/AU2017316255C1/en active Active
-
2019
- 2019-02-21 IL IL264956A patent/IL264956B2/en unknown
- 2019-03-22 ZA ZA2019/01781A patent/ZA201901781B/en unknown
-
2024
- 2024-04-17 AU AU2024202527A patent/AU2024202527B2/en active Active
- 2024-07-22 US US18/780,086 patent/US20250041409A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Claudin18. 2 is a novel molecular biomarker for tumor-targeted immunotherapy | |
| JP2019533475A5 (enExample) | ||
| JP2020534250A5 (enExample) | ||
| CA2786417C (en) | Methods for treating colorectal cancer | |
| JP2010523096A5 (enExample) | ||
| IL264956B2 (en) | Anti-pd1 monoclonal antibody, pharmaceutical preparation thereof and use thereof | |
| JP2021502810A5 (enExample) | ||
| JP2020507571A5 (enExample) | ||
| JP2005538701A5 (enExample) | ||
| CN104302667A (zh) | 外来体检测用单克隆抗体 | |
| JP2016503295A5 (enExample) | ||
| JP2023145569A (ja) | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 | |
| RU2015143208A (ru) | Высокоаффинные антитела kgd2 | |
| Michelakos et al. | B7-H3 targeted antibody-based immunotherapy of malignant diseases | |
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| JP2021520208A5 (enExample) | ||
| JP2008509086A5 (enExample) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| US20150175712A1 (en) | Antagonist to an enzyme and/or a metabolite of the kynurenine pathway | |
| JP2020501598A5 (enExample) | ||
| Xia et al. | Preparation and characterization of anti-GPC3 nanobody against hepatocellular carcinoma | |
| JP2018528759A5 (enExample) | ||
| JP2017538439A5 (enExample) | ||
| WO2014068300A1 (en) | Anti-s100a4 antibody molecules and their uses | |
| Li et al. | Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets |